Patents-Review.com
🔗 Permalink
Assignee profile:

Humanigen, Inc.

City:

Burlingame, California

Country:

United States

Published Applications:

18

Last publication date:

2022-11-17

Patent Grants:

7

Last grant date:

2024-11-12

Top Inventors for applications by Humanigen, Inc.

These are the the leading inventors for applications assigned to Humanigen, Inc.:

Recent patent applications by Humanigen, Inc.

Humanigen, Inc. based in Burlingame, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-11-17
US20220363746A1
Chemistry; metallurgy

METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY

 #2 | 2022-02-10
US20220040229A1
Human necessities

MATERIALS AND METHODS FOR TREATING CANCER

 #3 | 2022-01-27
US20220025034A1
Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

 #4 | 2021-10-21
US20210322547A1
Human necessities

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

 #5 | 2021-10-07
US20210309733A1
Chemistry; metallurgy

METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY

 #6 | 2021-09-23
US20210290677A1
Human necessities

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

 #7 | 2021-09-16
US20210284714A1
Chemistry; metallurgy

MATERIALS AND METHODS FOR TREATING CANCER

 #8 | 2021-09-02
US20210269518A1
Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

 #9 | 2021-08-12 ✅ Patent 12,139,544 granted on 2024-11-12
US20210246215A1
Chemistry; metallurgy

EphA3 directed CAR-T cells for treatment of tumors

 #10 | 2021-07-29
US20210230262A1
Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

 #11 | 2021-05-06
US20210130488A1
Chemistry; metallurgy

METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

 #12 | 2020-11-12 ✅ Patent 11,673,962 granted on 2023-06-13
US20200354443A1
Chemistry; metallurgy

Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab

 #13 | 2019-11-07 ✅ Patent 10,927,168 granted on 2021-02-23
US20190338023A1
Chemistry; metallurgy

Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab

 #14 | 2019-10-24 ✅ Patent 11,130,805 granted on 2021-09-28
US20190322735A1
Chemistry; metallurgy

Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist

 #15 | 2019-09-19 ✅ Patent 10,899,831 granted on 2021-01-26
US20190284271A1
Chemistry; metallurgy

Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity

 #16 | 2019-09-05
US20190270821A1
Chemistry; metallurgy

EPHA3 ANTIBODIES FOR THE TREATMENT OF PULMONARY FIBROSIS

 #17 | 2019-06-27 ✅ Patent 10,870,703 granted on 2020-12-22
US20190194343A1
Chemistry; metallurgy

Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist

 #18 | 2016-04-14 ✅ Patent 10,919,983 granted on 2021-02-16
US20160102152A1
Chemistry; metallurgy

Immunoglobulin variable region cassette exchange

Also check out HUMANIGEN, INC.'s (Burlingame, United States) applicant profile with 6 patent applications submitted.

AssigneeID:

150209 ⎘